OpenAI has acquired Orchestra Bio, a four-year-old startup that builds AI agents for biotech operations. The two companies' announcements agree on the basic deal, but TechCrunch adds that terms were not disclosed and that Orchestra had raised about $20 million from investors including Andreessen Horowitz, Atria, and 8VC.
TechCrunch reports that Orchestra's software handles the operational side of drug discovery, such as tracking finances and resolving scheduling issues in clinical trials. OpenAI says it will fold the startup's team and technology into Rosalind, its AI model for life sciences research, and into Rosalind Workbench, a tool for planning experiments and analyzing results. OpenAI's own post describes the acquisition more broadly as bringing AI-powered operations to life sciences R&D.
The acquisition illustrates how major AI labs are building software for large industries, TechCrunch notes, and it comes as OpenAI already counts Moderna and Novo Nordisk among Rosalind's customers. The sources do not conflict; OpenAI's announcement is simply shorter and omits the operational and strategic detail that TechCrunch provides.